[
  {
    "ts": null,
    "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
    "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
    "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757962258,
      "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
      "id": 136767795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428756484/image_1428756484.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
      "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation",
    "summary": "Merck (MRK) experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-class cancer treatment. Despite these positive advancements, the company's price movement aligns with broader market trends marked by record highs in Nasdaq and S&P 500 indices amid anticipated interest rate cuts. Alongside corporate earnings pressure and sales guidance...",
    "url": "https://finnhub.io/api/news?id=86d7969a89eba12c776fe9728be7e28feb8b637daca3069a5c34c461d6cd1541",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757960834,
      "headline": "Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation",
      "id": 136765931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-class cancer treatment. Despite these positive advancements, the company's price movement aligns with broader market trends marked by record highs in Nasdaq and S&P 500 indices amid anticipated interest rate cuts. Alongside corporate earnings pressure and sales guidance...",
      "url": "https://finnhub.io/api/news?id=86d7969a89eba12c776fe9728be7e28feb8b637daca3069a5c34c461d6cd1541"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=54430c667285ac05168cb42937e238fbc31ea7f6478d456732e2327160ed0ef2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757954040,
      "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
      "id": 136776342,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=54430c667285ac05168cb42937e238fbc31ea7f6478d456732e2327160ed0ef2"
    }
  },
  {
    "ts": null,
    "headline": "Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT",
    "summary": "Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the company’s masking platform has the potential to overcome the limitations of T-cell engagers in solid tumors by […]",
    "url": "https://finnhub.io/api/news?id=a3f063e6690fe94606ca839d7db80377c3768ebf4ad700531181932650141ed2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757945366,
      "headline": "Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT",
      "id": 136749578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the company’s masking platform has the potential to overcome the limitations of T-cell engagers in solid tumors by […]",
      "url": "https://finnhub.io/api/news?id=a3f063e6690fe94606ca839d7db80377c3768ebf4ad700531181932650141ed2"
    }
  },
  {
    "ts": null,
    "headline": "Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., September 15, 2025--Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab.",
    "url": "https://finnhub.io/api/news?id=82d03171ff7007ebc980eb1def8b48a956242ff45145cf3c12b4ba9da38201d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757937600,
      "headline": "Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab",
      "id": 136749579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., September 15, 2025--Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab.",
      "url": "https://finnhub.io/api/news?id=82d03171ff7007ebc980eb1def8b48a956242ff45145cf3c12b4ba9da38201d6"
    }
  },
  {
    "ts": null,
    "headline": "How Bad Is This Sector’s Health Scare?",
    "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
    "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757937307,
      "headline": "How Bad Is This Sector’s Health Scare?",
      "id": 136749580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
      "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: AstraZeneca Pauses $271 Million Cambridge Project",
    "summary": "(Updates with comments from AstraZeneca in the first paragraph and stock move in the fifth paragraph",
    "url": "https://finnhub.io/api/news?id=59ee60fee2c6b356972f16fdeb324bd08b3d5dfa22f6bfe703e0980563b48315",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757930880,
      "headline": "Update: Market Chatter: AstraZeneca Pauses $271 Million Cambridge Project",
      "id": 136749581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "(Updates with comments from AstraZeneca in the first paragraph and stock move in the fifth paragraph",
      "url": "https://finnhub.io/api/news?id=59ee60fee2c6b356972f16fdeb324bd08b3d5dfa22f6bfe703e0980563b48315"
    }
  }
]